{"preliminary_commentary":{"by_channel":{"youtube":7,"podcast":6,"bluesky_thread":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04095364\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"NRG-GY019","nct_id":"NCT04095364","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nrg-gy019-nct04095364. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Cycles repeat every 21 days for up to 6 cycles. Patients then receive letrozole PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection and tumor biopsy during screening as well as medical imaging throughout the study.","label":"Arm I (paclitaxel, carboplatin, letrozole)","type":"EXPERIMENTAL"},{"description":"Patients receive letrozole PO QD. Cycles repeat every 21 days for up to 6 cycles. Patients then receive letrozole orally PO QD in the absence of disease progression or unacceptable toxicity as maintenance therapy. Patients undergo blood collection and tumor biopsy during screening as well as medical imaging throughout the study.","label":"Arm II (letrozole)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2028-02-01","type":"ESTIMATED"},"conditions":["Low Grade Fallopian Tube Serous Adenocarcinoma","Ovarian Low Grade Serous Adenocarcinoma","Primary Peritoneal Low Grade Serous Adenocarcinoma","Stage II Fallopian Tube Cancer AJCC v8","Stage II Ovarian Cancer AJCC v8","Stage II Primary Peritoneal Cancer AJCC v8","Stage III Fallopian Tube Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Primary Peritoneal Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8"],"enrollment":{"count":450,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biopsy Procedure","otherNames":["Biopsy","BIOPSY_TYPE","Bx"],"type":"PROCEDURE"},{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carboplatinum","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","JM8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"],"type":"DRUG"},{"name":"Imaging Procedure","otherNames":["Diagnostic Imaging Technique","Image Type","Imaging","Imaging (procedure)","Imaging Procedures","Imaging Technique","imaging type","IMAGING_METHOD","imaging_type","Medical Imaging","Type of imaging"],"type":"PROCEDURE"},{"name":"Letrozole","otherNames":["CGS 20267","CGS-20267","CGS20267","Femara","Fempro"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Anzatax","Asotax","Bristaxol","Praxel","Taxol","Taxol Konzentrat"],"type":"DRUG"}],"last_update":"2026-03-24","lead_sponsor":"NRG Oncology","official_title":"A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-02-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"Time from the randomized treatment assignment to documentation of disease progression (Response Evaluation Criteria in Solid Tumors 1.1) or death from any cause, whichever comes first, assessed up to 8 years"}],"references":[{"citation":"Ilenkovan N, Ryan N, Roxburgh P, Bell S, Gourley C. Controversies in the management of serous borderline tumors and low-grade serous ovarian cancer. Int J Gynecol Cancer. 2025 Mar;35(3):101673. doi: 10.1016/j.ijgc.2025.101673. Epub 2025 Jan 30.","pmid":"40058134","type":"DERIVED"}],"start_date":{"date":"2019-09-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","url":"https://clinicaltrials.gov/study/NCT04095364"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nrg-gy019-nct04095364"}